WO2012028522A1 - Alkaline feed - Google Patents
Alkaline feed Download PDFInfo
- Publication number
- WO2012028522A1 WO2012028522A1 PCT/EP2011/064598 EP2011064598W WO2012028522A1 WO 2012028522 A1 WO2012028522 A1 WO 2012028522A1 EP 2011064598 W EP2011064598 W EP 2011064598W WO 2012028522 A1 WO2012028522 A1 WO 2012028522A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino acid
- cell
- alkaline solution
- leucine
- cultivating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
Definitions
- a method for high cell density cultivation of a prokaryotic cell such as an Escherichia coli strain, in a chemically defined medium for the production of a polypeptide wherein an amino acid is fed by a concentrated alkaline solution simultaneously regulating the pH of the cultivation medium and acting as a nitrogen source.
- Cell cultures are used in fermentative processes to produce substances and in particular proteins. A distinction is made between processes in which the cell cultures are genetically unmodified and form their own metabolic products and processes in which the organisms are genetically modified in such a manner that they either produce a larger amount of their own substances such as proteins or produce foreign substances.
- the organisms producing the substances are supplied with a nutrient medium which guarantees the survival of the organisms and enables the production of the desired target compound. Numerous culture media are known for these purposes which enable an optimal cultivation of the specific host. High-cell-density cultivation of Escherichia coli is reported by Riesenberg (Riesenberg, D., et al., Curr. Opin. Biotechnol.
- WO 91/10721 a process for high cell density fermentation of Escherichia coli in an agitated boiler fermenter is reported. A method of plasmid DNA production and purification is reported in WO 97/29190. The controlling of growth of aerobic submerged microorganism cultures by controlling dissolved oxygen concentration and oxygen transfer rate is reported in DD 295867.
- EP 0 866 876 a process for the preparation of recombinant proteins in E.coli by high cell density fermentation is reported.
- WO 03/048374 a process for the production of aromatic amino acid metabolite or derivative thereof is reported. A process for the preparation of recombinant proteins in E.coli by high cell density fermentation is reported in WO 97/21829.
- a prokaryotic cell especially an amino acid auxotrophic E.coli K12 strain, can be cultivated on chemically defined medium at high cell densities if an amino acid is added to the cultivation medium in an alkaline solution.
- One aspect as reported herein is a method for cultivating a bacterial cell, especially an E.coli cell, at high cell densities, wherein the cell expresses a recombinant polypeptide, wherein the cultivating comprises the adding of an alkaline solution of an amino acid selected from aspartate, aspartic acid, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, tryptophan and tyrosine during the cultivating,
- amino acid has a concentration in the alkaline solution that is higher than its solubility in water at 20 °C and at neutral pH
- dry cell weight of the cultivated bacterial cell is at one point in the cultivating at least 20 g/1.
- One aspect as reported herein is a method for producing a polypeptide comprising the steps
- an alkaline solution comprising an amino acid selected from aspartate, aspartic acid, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, tryptophan and tyrosine,
- Another aspect as reported herein is the use of an alkaline solution comprising an amino acid for adjusting the pH value during the cultivation of a bacterial cell.
- an aspect as reported herein is the use of an alkaline solution of an amino acid as feed in the cultivation of a bacterial cell, wherein the amino acid is selected from aspartate, aspartic acid, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, tryptophan and tyrosine and the cultivation is up to a dry cell weight of 20 g/1 or more.
- the amino acid is a poorly water soluble amino acid.
- the bacterial cell is an amino acid auxotrophic cell and the auxotrophy is for an amino acid selected from aspartate, aspartic acid, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, tryptophan and tyrosine.
- the bacterial cell is an Escherichia coli cell or mutant thereof.
- the amino acid has a solubility in water at 20 °C of 50 g/1 or less.
- the amino acid has a solubility in water at 20 °C of 40 g/1 or less.
- the amino acid is selected from aspartate, aspartic acid, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, tryptophan and tyrosine.
- the amino acid is selected from aspartate, aspartic acid, glutamine, glutamic acid, histidine, leucine, tryptophan and tyrosine.
- the amino acid is leucine.
- the amino acid has a concentration in the alkaline solution that is higher than its solubility in water at 20 °C.
- the solubility is two times higher, in another embodiment three times higher than the solubility in water at 20 °C. In another embodiment the solubility is higher than the solubility in water at 20 °C and at a pH value of pH 6 to 8.
- the amino acid has a concentration of 25 g/1 or more in the alkaline solution, or in a further embodiment of 30 g/1 or more, or in still another embodiment of 35 g/1 or more. In one embodiment the amino acid has a concentration of 45 g/1 or more in the alkaline solution. In one embodiment the amino acid has a concentration of about 50 g/1 in the alkaline solution.
- the alkaline solution has a pH value of 9 or more, in a further embodiment of 10 or more, and still in another embodiment of 10.5 or more.
- the alkaline solution is an ammonia solution of more than 5 % (w/v), or of 10% (w/v) or more, or of 15 % (w/v) or more.
- the alkaline solution is an ammonia solution of about 12.5 % (w/v) in water.
- the polypeptide is human apolipoprotein Al or a derivative thereof.
- the apolipoprotein Al has an amino acid sequence selected from of SEQ ID NO: 01 to SEQ ID NO: 35.
- the polypeptide has an amino acid sequence selected from SEQ ID NO: 01, SEQ ID NO: 02,
- a method for cultivating a prokaryotic cell e.g. an amino acid auxotrophic bacterial cell, wherein at least one amino acid, e.g. that for which the cell is auxotrophic, is added in an alkaline solution.
- a prokaryotic cell e.g. an amino acid auxotrophic E.coli K12 strain
- a feed comprising at least one amino acid such as that for which the cell has an auxotrophy
- the alkaline solution can be used to adjust the pH value of the cultivation medium.
- c) adjusting the pH value during the cultivating of the prokaryotic cell with an alkaline solution comprising an amino acid selected from aspartate, aspartic acid, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, tryptophan and tyrosine.
- amino acid auxotrophic prokaryotic cell is a prokaryotic cell that cannot synthesize an essential amino acid e.g. due to a mutation or deletion within a gene locus comprising the structural gene encoding the proteins of the corresponding biosynthetic pathway. Without the addition of the respective amino acid to the cultivation medium the cell cannot proliferate.
- the auxotrophy can be for any amino acid.
- the prokaryotic cell can also be auxotrophic for more than one amino acid.
- the amino acid auxotrophic prokaryotic cell is auxotrophic for at least one amino acid.
- amino acid auxotrophic prokaryotic cell is auxotrophic for at least one, at least two, at least three, at least four, at least five amino acids. In a further embodiment the amino acid auxotrophic prokaryotic cell is auxotrophic for up to 5, or up to 10, or up to 15 amino acids. In another embodiment the amino acid auxotrophic prokaryotic cell is auxotrophic for one to five amino acids, or one to three amino acids, or for one to two amino acids, or for one amino acid, or for two amino acids, or for three amino acids, or for four amino acids.
- the amino acid auxotrophic prokaryotic cell is in one embodiment a bacterial cell.
- the cell is an Escherichia cell, or a Bacillus cell, or a Lactobacillus cell, or a Corynebacterium cell, or a Yeast cell (Saccharomyces, Candida, or Pichia).
- the cell is an Escherichia coli cell, or a Bacillus subtilis cell, or a Lactobacillus acidophilus cell, or a Corynebacterium glutamicum cell, or a Pichia pastoris yeast cell.
- adjusting a value denotes that the respective value is maintained at a predetermined level throughout a cultivating, i.e. the value is checked continuously or at predetermined constant time intervals and change by the addition of a correction fluid if the value is outside a preset acceptance range.
- the term “adjusting the pH value” denotes that the pH value of a cultivation medium is determined periodically at fixed time points, i.e. with fixed time intervals, and if the determined pH value is outside an acceptance range, such as e.g. 0.1 pH units or 0.15 pH units or 0.2 pH units, the pH value is re-adjusted to the predetermined pH value by the addition of a correction fluid, such as an acid or an alkaline solution.
- cultivating can be with any method.
- the cultivating is a batch cultivating, a fed-batch cultivating, a perfusion cultivating, a semi-continuous cultivating, or a cultivating with full or partial cell retention.
- the only requirement for the cultivating is that an alkaline solution has to be added. This addition can be a sole feed solution or as a combined feed and pH adjustment solution.
- the cultivation medium used for the start of the cultivating of the cell can be any medium known to a person skilled in the art, whereby the concentration of the amino acid to be fed is in the medium less than 5 g/1, or less than 7.5 g/1, or less than 10 g/1. It has to be pointed out that the concentration of the respective compounds has to be chosen in a way that no negative interference with the growth of the cell is to be expected.
- the medium a defined glucose-mineral salt medium.
- the cultivating is a high cell density cultivating.
- high cell density cultivating denotes a cultivating method wherein the dry cell weight of the cultivated prokaryotic cell is at one point in the cultivating at least 10 g/1. In one embodiment the dry cell weight is at one point in the cultivating at least 20 g/1, or at least 50 g/1, or at least 100 g/1, or more than 100 g/1. In order to reach such a high cell density state the volume of feed and/or adjustment solutions added during the cultivating has to be as small as possible. Methods for the determination of dry cell weight are reported e.g. in Riesenberg, D., et al., Appl. Microbiol. Biotechnol. 34 (1990) 77-82.
- the nutrients in the provided medium will be metabolized during the cultivation and have to be replenished in order to avoid a limitation. If an amino acid has a poor solubility only a lowly concentrated feed solution can be prepared and added. To provide the required amount of the amino acid a large volume of the feed solution has to be added. This results in an increase in the total cultivation volume, a dilution of the culture broth and, thus, is disadvantageous for a high cell density processes.
- the solubility of the 20 naturally occurring amino acids is listed in the following
- the solubility of the amino acids aspartate, aspartic acid, glutamine, glutamic acid, histidine, isoleucine, leucine, methionine, phenylalanine, tryptophan and tyrosine is below 50 g/1 and, thus, these amino acids are termed to have a poor solubility in water.
- the amino acid leucine has a solubility in water at 20 °C of 24 g/1 and, thus, is poorly soluble.
- an alkaline solution comprising 12.5 % (w/v) ammonia the solubility is increased to 76 g/1 and, thus, is more than three times the solubility in water. At the same time the required feed volume is reduced by more than 60 %.
- the alkaline solution is also used to adjust the pH value of the cultivation the added volume can be reduced even more.
- the amino acid tyrosine has a solubility in water at 20 °C of 0.4 g/1 and, thus, is poorly soluble.
- an alkaline solution comprising 12.5 % (w/v) ammonia the solubility is increased to 39 g/1 and, thus, is about one hundred times the solubility in water.
- the amino acid is aspartate, aspartic acid, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, tryptophan and/or tyrosine.
- the amino acid is aspartate, aspartic acid, glutamine, glutamic acid, histidine, leucine, tryptophan and/or tyrosine.
- the amino acid is leucine.
- the amino acid is an amino acid that it poorly soluble in water of a pH value of about 7 at 20 °C.
- the amino acid is leucine and proline, or the amino acid is leucine and proline and tryptophan.
- the amino acid has a solubility in the alkaline solution that is higher than the solubility in water at 20 °C.
- the solubility in the alkaline solution is of from two times to ten times the solubility in water at 20 °C.
- the amino acid has a solubility in water of 40 g/1 or less.
- the amino acid has a solubility in water of 30 g/1 or less.
- the amino acid has a solubility in the alkaline solution of 25 g/1 or more.
- the amino acid has a concentration in the alkaline solution of 30 g/1 or more. In another embodiment the amino acid has a concentration in the alkaline solution of 35 g/1 or more. In also an embodiment the amino acid has a solubility in the alkaline solution of 50 g/1 or more.
- the alkaline solution is a 12.5 % (w/v) ammonia solution in water and comprises at least one amino acid at a concentration of about 50 g/1 or more. In one embodiment the alkaline solution comprises Leucine and Proline at a concentration of about 50 g/1.
- Prokaryotic cells that can be used in the method as reported herein can comprise one or more amino acid auxotrophies.
- E.coli cells deficient in the Leucine biosynthetic pathway can be selected from the LeuB6 deficient cells 13-6, ⁇ 148, ⁇ 156, ⁇ 2224, ⁇ 462, ⁇ 463, ⁇ 474, ⁇ 478, ⁇ 515, ⁇ 65, ⁇ 697, ⁇ 760, 2000k MSE248, 342-167, 342MG, 679-680, ⁇ 586, ⁇ 592, ⁇ 593, AA100, ⁇ 7852, ⁇ 787, AB 1102, AB1111, AB 1115, AB1122, AB 1129, AB113, AB 1132, AB1133, AB114, AB 1157, AB1157-D, AB1314, AB 1330, AB1331, AB1881, AB1884, AB1885, AB 188, CP78, CP79, CR34 Thy-, CR34 Th
- the alkaline solution is a strongly alkaline solution.
- the alkaline solution has a pH value of pH 9 or more, or pH 10 or more, or pH 10.5 or more.
- the solubility of the amino acid in the alkaline solution is at least twice the solubility of the amino acid in water.
- a method for cultivating an Escherichia coli cell expressing a polypeptide characterized in that the cultivating comprises the adding of an alkaline solution of an amino acid selected from aspartate, aspartic acid, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, tryptophan and tyrosine during the cultivating, wherein the amino acid has a concentration in the alkaline solution that is higher than its solubility in water at 20 °C and at neutral pH, and the amino acid has a concentration of 30 g/1 or more, and wherein the alkaline solution is an ammonia solution of 10% (w/v) or more, and wherein the dry cell weight of the cultivated bacterial cell is at one point in the cultivating at least 20 g/1.
- an amino acid selected from aspartate, aspartic acid, glutamine, glutamic acid, glycine, histidine, isoleucine,
- an alkaline solution comprising an amino acid selected from aspartate, aspartic acid, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, tryptophan and tyrosine, d) recovering the polypeptide from the cell or the cultivation medium and thereby producing the polypeptide, wherein the amino acid has a concentration in the alkaline solution of 30 g/1 or more, and wherein the alkaline solution is an ammonia solution of 10% (w/v) or more.
- the bacterial cell is an amino acid auxotrophic cell and the auxotrophy is for an amino acid selected from aspartate, aspartic acid, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, tryptophan and tyrosine.
- the alkaline solution has a pH value of 9 or more.
- the polypeptide is human apolipoprotein Al or a derivative thereof.
- Method according to embodiment 5 characterized in that the apolipoprotein Al has an amino acid sequence selected from SEQ ID NO: 01 to 35.
- the method according to any one of the preceding embodiments characterized in that the amino acid has a concentration of about 50 g/1.
- the method according to any one of the preceding embodiments, characterized in that the alkaline solution is an ammonia solution of about 12.5 % (w/v) of ammonia in water.
- the method according to any one of the preceding embodiments, characterized in that the amino acid is leucine.
- the alkaline solution comprises leucine and proline.
- an alkaline solution of an amino acid as feed in the cultivation of a bacterial cell, wherein the amino acid is selected from aspartate, aspartic acid, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, tryptophan and tyrosine, and the cultivation is up to a dry cell weight of 20 g/1 or more, and the amino acid has a concentration of 30 g/1 or more in the alkaline solution and the alkaline solution is an ammonia solution of 10 % (w/v) or more.
- the bacterial cell is an amino acid auxotrophic cell and the auxotrophy is for an amino acid selected from aspartate, aspartic acid, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, tryptophan and tyrosine.
- Optical density of the cultivations was measured with a DR2800 photometer (Hach-Lange, Dusseldorf, Germany) at 578 nm.
- Protein concentration was determined densitometrically by comparing the volumes of a standard protein band with the band volumes of the produced protein within the fermentation samples on a SDS-Page gel.
- the calculated amount of Leucine was weighted into a 500 ml flask. After addition of 250 ml deionized water the solution is sterilized by autoclavation. Thereafter 250 ml of a 25 % (w/v) ammonia solution is added and determined whether the Leucine was dissolved or not. After dissolution of the Leucine the final volume of the solution was determined. If it deviates notably from 500 ml the solution was prepared again with a reduced amount of water (see Table 3).
- the tetranectin-apolipoprotein A-I fusion polypeptide was prepared by recombinant means.
- the amino acid sequence of the expressed fusion polypeptide in N- to C-terminal direction is as follows:
- HHHHHH SEQ ID NO: 37
- VVAPPAP an IgA protease cleavage site that has the amino acid sequence of VVAPPAP (SEQ ID NO: 38), and
- the tetranectin-apolipoprotein A-I fusion polypeptides as described above are precursor polypeptides from which the tetranectin-apolipoprotein A-I fusion polypeptides was released by enzymatic cleavage in vitro using IgA protease.
- the precursor polypeptide encoding fusion gene was assembled with known recombinant methods and techniques by connection of appropriate nucleic acid segments. Nucleic acid sequences made by chemical synthesis were verified by DNA sequencing. The expression plasmid for the production of tetranectin-apolipoprotein A-I was prepared as follows.
- Plasmid 4980 (4980-pBRori-URA3-LACI-SAC) is an expression plasmid for the expression of core-streptavidin in E. coli. It was generated by ligation of the 3142 bp long EcoRI/Celll-vector fragment derived from plasmid 1966 (1966-pBRori- URA3-LACI-T-repeat; reported in EP-B 1 422 237) with a 435 bp long core-streptavidin encoding EcoRI/Celll-fragment.
- the core-streptavidin E.coli expression plasmid comprises the following elements: the origin of replication from the vector pBR322 for replication in E.
- coli (corresponding to bp position 2517-3160 according to Sutcliffe, J.G., et al., Quant. Biol. 43 (1979) 77-90), the URA3 gene of Saccharomyces cerevisiae coding for orotidine 5'- phosphate decarboxylase (Rose, M., et al., Gene 29 (1984) 113-124) which allows plasmid selection by complementation of E.coli pyrF mutant strains (uracil auxotrophy), the core-streptavidin expression cassette comprising the T5 hybrid promoter (T5-PN25/03/04 hybrid promoter according to Bujard, H., et al., Methods. Enzymol.
- the final expression plasmid for the expression of the tetranectin-apolipoprotein A-I precursor polypeptide was prepared by excising the core-streptavidin structural gene from vector 4980 using the singular flanking EcoRI and Celll restriction endonuclease cleavage site and inserting the EcoRII/Celll restriction site flanked nucleic acid encoding the precursor polypeptide into the 3142 bp long EcoRI/CelII-4980 vector fragment.
- the E.coli K12 strain CSPZ-2 (leuB, proC, trpE, th-1, ApyrF) was used.
- the strain was transformed with an expression plasmid for the production of a therapeutic protein and maintained as primary seed bank in ampoules containing 1 ml of the strain grown on defined pre-culture medium to an optical density (determined at 578 nm) of approximately 1 and 1 ml of glycerol 85% (v/v) and stored at -80°C.
- the defined pre-culture medium was a M9 medium according to Sambrook, J., et al., Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989) supplemented with
- the batch medium was supplemented with
- Feed 2 and 3 were prepared by weighting the amino acid, dissolving the amino acids in water, and autoclaving the solution. Afterwards the pH value of the solution has been determined to be about 6.15 for feed 2 and about 6.43 for feed 3.
- the alkaline solution employed for pH regulation was an aqueous 12.5 % (w/v) H 3 solution.
- the main fermentation was carried out in 10 1 Biostat C DCU3 fermenter (Sartorius, Melsungen, Germany). Starting with 6.4 1 sterile batch medium plus 300 ml pre-cultivation the batch fermentation was carried out at 37 °C, pH 6.9 ⁇ 0.2, 500 mbar and an aeration rate of 10 1/min. After the initially supplemented glucose was depleted the temperature was shifted to 28 °C and the fermentation entered the fed-batch mode with dissolved oxygen (p02) kept at 50 % (DO-stat, see e.g.
- the flow rates were calculated from a separate fermentation run (see example 4), to respectively apply exactly the same amount of amino acids to the cultivations independently from the feeding strategy.
- the expression of recombinant therapeutic protein was induced by the addition of 1 mM IPTG at an optical density of 70.
- the p02-feed control was started and p02 was controlled at 50 % by the addition of feed 1 while continuously increasing agitation and aeration rate to their respective maxima of 1400 rpm and 20 1/min.
- the growth rate was continuously decreasing from 0.15 to approximately 0.05 1/h.
- the stirrer speed was reduced stepwise after 36 hours of cultivation. When no further increase in optical density could be determined the fermentation was terminated and bacteria cells where cooled to 4 °C over night before harvest.
- amino acid feeding was incorporated in the alkaline pH control solution.
- the basis of this fermentation is the same high cell density cultivation method according to Riesenberg, et al., (1991, supra) as used in Example 3.
- the amino acids L-Leucine and L-Proline were incorporated in the aqueous 12.5 % H 3 solution and fed with alkali addition during pH control.
- the E.coli K12 strain CSPZ-2 (leuB, proC, trpE, th-1, ApyrF) was used.
- the strain was transformed with an expression plasmid for the production of a therapeutic protein and maintained as primary seed bank in ampoules containing 1 ml of the strain grown on defined pre-culture medium to an optical density (determined at
- the defined pre-culture medium was a M9 medium according to Sambrook, J., et al., (Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989)) supplemented with
- the batch medium was supplemented with
- the alkaline solution employed for pH regulation was an aqueous 12.5 % (w/v) NH 3 solution supplemented with 50 g/1 L-Leucine and 50 g/1 L-Proline respectively.
- the optical density at fermentation end was 169 and the total biomass yield was 75.7 g/1 (dry matter). During the fermentation almost no acetate was excreted and towards the end concentrations increased to 1 g/1. The recombinant protein formation yielded 16.5 g/1. The volume of the culture broth was 10.2 1. The fermentation was repeated with different amounts of amino acids dissolved within the alkali solution (33 g/1 of L-Leucine and L-Proline). The amount of fed amino acids was lower and resulted in an optical density of 145, end biomass yield of 56.5 g/1, and recombinant protein yield of 13.5 g/1, culture broth volume at the end of fermentation was 9.3 1.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201180041407.3A CN103068967B (en) | 2010-08-30 | 2011-08-25 | Alkalescence charging |
BR112013004396A BR112013004396A2 (en) | 2010-08-30 | 2011-08-25 | alkaline power |
JP2013526412A JP5798193B2 (en) | 2010-08-30 | 2011-08-25 | Alkaline feed |
ES11748406.3T ES2558751T3 (en) | 2010-08-30 | 2011-08-25 | Alkaline food |
CA2807428A CA2807428A1 (en) | 2010-08-30 | 2011-08-25 | Alkaline feed comprising amino acids for culturing e. coli |
RU2013112563A RU2631001C2 (en) | 2010-08-30 | 2011-08-25 | Method of obtaining polypeptide |
KR1020137007871A KR101584414B1 (en) | 2010-08-30 | 2011-08-25 | Alkaline feed |
MX2013002144A MX339227B (en) | 2010-08-30 | 2011-08-25 | Alkaline feed. |
EP11748406.3A EP2611900B1 (en) | 2010-08-30 | 2011-08-25 | Alkaline feed |
HK13109024.6A HK1181811A1 (en) | 2010-08-30 | 2013-08-02 | Alkaline feed |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10008997.8 | 2010-08-30 | ||
EP10008997 | 2010-08-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012028522A1 true WO2012028522A1 (en) | 2012-03-08 |
Family
ID=43088050
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2011/064598 WO2012028522A1 (en) | 2010-08-30 | 2011-08-25 | Alkaline feed |
Country Status (12)
Country | Link |
---|---|
US (2) | US8951756B2 (en) |
EP (1) | EP2611900B1 (en) |
JP (2) | JP5798193B2 (en) |
KR (1) | KR101584414B1 (en) |
CN (1) | CN103068967B (en) |
BR (1) | BR112013004396A2 (en) |
CA (1) | CA2807428A1 (en) |
ES (1) | ES2558751T3 (en) |
HK (1) | HK1181811A1 (en) |
MX (1) | MX339227B (en) |
RU (1) | RU2631001C2 (en) |
WO (1) | WO2012028522A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8791063B2 (en) | 2011-08-25 | 2014-07-29 | Hoffmann-La Roche, Inc. | Shortened tetranectin-apolipoprotein A-I fusion protein, a lipid particle containing it, and uses thereof |
WO2014128135A1 (en) | 2013-02-22 | 2014-08-28 | F. Hoffmann-La Roche Ag | Use of an amino acid auxotrophy cured prokaryotic strain for the recombinant production of a polypeptide |
US20150011469A1 (en) * | 2012-01-19 | 2015-01-08 | University Of Cincinnati | Method of treating diabetes using non-glycosylated apolipoprotein a-iv |
EP3184547A1 (en) | 2015-10-29 | 2017-06-28 | F. Hoffmann-La Roche AG | Anti-tpbg antibodies and methods of use |
US11332514B2 (en) | 2011-08-25 | 2022-05-17 | Hoffmann-La Roche Inc. | Cation and anion exchange chromatography method |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112013004396A2 (en) * | 2010-08-30 | 2016-05-17 | Hoffmann La Roche | alkaline power |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991010721A2 (en) | 1990-01-19 | 1991-07-25 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Process for high cell density fermentation of escherichia coli in an agitated boiler fermenter |
DD295867A5 (en) | 1988-07-28 | 1991-11-14 | Zi F. Mikrobiologie U. Exper. Therapie, | PROCESS FOR CONTROLLING THE GROWTH OF AEROB SUBMERSES MICROORGANISMS CULTURES |
WO1997021829A1 (en) | 1995-12-11 | 1997-06-19 | Merck Patent Gmbh | Process for the preparation of recombinant proteins in e.coli by high cell density fermentation |
WO1997029190A1 (en) | 1996-02-12 | 1997-08-14 | Cobra Therapeutics Limited | Method of plasmid dna production and purification |
WO2002038609A2 (en) * | 2000-11-10 | 2002-05-16 | Proteopharma Aps | Apolipoprotein conjugates |
WO2003048374A1 (en) | 2001-12-05 | 2003-06-12 | Dsm Ip Assets B.V. | Process for the production of an aromatic amino acid metabolite or derivative thereof |
EP1422237B1 (en) | 2002-11-19 | 2007-02-14 | F. Hoffmann-La Roche Ag | Methods for the recombinant production of antifusogenic peptides |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60118196A (en) * | 1983-11-30 | 1985-06-25 | Takeda Chem Ind Ltd | Production of interferon |
SE9203753D0 (en) * | 1992-12-11 | 1992-12-11 | Kabi Pharmacia Ab | EXPRESSION SYSTEM FOR PRODUCING APOLIPOPROTEIN AI-M |
US6291245B1 (en) * | 1998-07-15 | 2001-09-18 | Roche Diagnostics Gmbh | Host-vector system |
BR112013004396A2 (en) * | 2010-08-30 | 2016-05-17 | Hoffmann La Roche | alkaline power |
-
2011
- 2011-08-25 BR BR112013004396A patent/BR112013004396A2/en not_active IP Right Cessation
- 2011-08-25 ES ES11748406.3T patent/ES2558751T3/en active Active
- 2011-08-25 MX MX2013002144A patent/MX339227B/en active IP Right Grant
- 2011-08-25 CA CA2807428A patent/CA2807428A1/en not_active Abandoned
- 2011-08-25 KR KR1020137007871A patent/KR101584414B1/en not_active IP Right Cessation
- 2011-08-25 RU RU2013112563A patent/RU2631001C2/en not_active IP Right Cessation
- 2011-08-25 WO PCT/EP2011/064598 patent/WO2012028522A1/en active Application Filing
- 2011-08-25 CN CN201180041407.3A patent/CN103068967B/en not_active Expired - Fee Related
- 2011-08-25 JP JP2013526412A patent/JP5798193B2/en not_active Expired - Fee Related
- 2011-08-25 US US13/217,540 patent/US8951756B2/en not_active Expired - Fee Related
- 2011-08-25 EP EP11748406.3A patent/EP2611900B1/en not_active Not-in-force
-
2013
- 2013-08-02 HK HK13109024.6A patent/HK1181811A1/en not_active IP Right Cessation
-
2015
- 2015-01-28 US US14/607,932 patent/US9845347B2/en not_active Expired - Fee Related
- 2015-07-10 JP JP2015139021A patent/JP2016005461A/en active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DD295867A5 (en) | 1988-07-28 | 1991-11-14 | Zi F. Mikrobiologie U. Exper. Therapie, | PROCESS FOR CONTROLLING THE GROWTH OF AEROB SUBMERSES MICROORGANISMS CULTURES |
WO1991010721A2 (en) | 1990-01-19 | 1991-07-25 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Process for high cell density fermentation of escherichia coli in an agitated boiler fermenter |
WO1997021829A1 (en) | 1995-12-11 | 1997-06-19 | Merck Patent Gmbh | Process for the preparation of recombinant proteins in e.coli by high cell density fermentation |
EP0866876A1 (en) | 1995-12-11 | 1998-09-30 | MERCK PATENT GmbH | Process for the preparation of recombinant proteins in e.coli by high cell density fermentation |
WO1997029190A1 (en) | 1996-02-12 | 1997-08-14 | Cobra Therapeutics Limited | Method of plasmid dna production and purification |
WO2002038609A2 (en) * | 2000-11-10 | 2002-05-16 | Proteopharma Aps | Apolipoprotein conjugates |
WO2003048374A1 (en) | 2001-12-05 | 2003-06-12 | Dsm Ip Assets B.V. | Process for the production of an aromatic amino acid metabolite or derivative thereof |
EP1422237B1 (en) | 2002-11-19 | 2007-02-14 | F. Hoffmann-La Roche Ag | Methods for the recombinant production of antifusogenic peptides |
Non-Patent Citations (20)
Title |
---|
BECK, E., ZINK, B., GENE, 1981, pages 1 - 3,35-58 |
BUJARD, H. ET AL., METHODS. ENZYMOL., vol. 155, 1987, pages 416 - 433 |
FARABAUGH, P.J., NATURE, vol. 274, 1978, pages 765 - 769 |
HORN U ET AL: "HIGH VOLUMETRIC YIELDS OF FUNCTIONAL DIMERIC MINIANTIBODIES IN ESCHERICHIA COLI, USING AN OPTIMIZED EXPRESSION VECTOR AND HIGH-CELL-DENSITY FERMENTATION UNDER NON-LIMITED GROWTH CONDITIONS", APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, SPRINGER VERLAG, BERLIN, DE, vol. 46, no. 5/06, 1 January 1996 (1996-01-01), pages 524 - 532, XP000618868, ISSN: 0175-7598, DOI: DOI:10.1007/S002530050855 * |
HORN, U. ET AL., APPL. MICROBIOL. BIOTECHNOL., vol. 46, 1996, pages 524 - 532 |
MIZUTANI S ET AL: "EFFECT OF AMINO-ACID SUPPLEMENT ON CELL YIELD AND GENE PRODUCT IN ESCHERICHIA-COLI HARBORING PLASMID", BIOTECHNOLOGY AND BIOENGINEERING, vol. 28, no. 2, 1986, pages 204 - 209, XP002611934, ISSN: 0006-3592 * |
RIESENBERG D ET AL: "High-cell-density cultivation of microorganisms", APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, vol. 51, no. 4, April 1999 (1999-04-01), pages 422 - 430, XP002611932, ISSN: 0175-7598 * |
RIESENBERG D: "High-cell-density cultivation of Escherichia coli.", CURRENT OPINION IN BIOTECHNOLOGY JUN 1991 LNKD- PUBMED:1367825, vol. 2, no. 3, June 1991 (1991-06-01), pages 380 - 384, XP002611933, ISSN: 0958-1669 * |
RIESENBERG, D. ET AL., APPL. MICROBIOL. BIOTECHNOL., vol. 34, 1990, pages 77 - 82 |
RIESENBERG, D. ET AL., CURR. OPIN. BIOTECHNOL., vol. 2, 1991, pages 380 - 384 |
RIESENBERG, D., GUTHKE, R., APPL. MICROBIOL. BIOTECHNOL., vol. 51, 1999, pages 422 - 430 |
ROSE, M. ET AL., GENE, vol. 29, 1984, pages 113 - 124 |
SAMBROOK, J. ET AL.: "Molecular Cloning: A Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY PRESS |
SANG Y L: "High cell-density culture of Escherichia coli", TRENDS IN BIOTECHNOLOGY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 14, no. 3, 1 March 1996 (1996-03-01), pages 98 - 105, XP004035826, ISSN: 0167-7799, DOI: DOI:10.1016/0167-7799(96)80930-9 * |
SCHWARZ, E. ET AL., NATURE, vol. 272, 1978, pages 410 - 414 |
SHAY, L.K. ET AL., J. INDUS. MICROBIOL., vol. 2, 1987, pages 79 - 85 |
SHILOACH, J., FASS, R., BIOTECHNOL. ADVANCES, vol. 23, 2005, pages 345 - 357 |
STUEBER, D. ET AL., IMMUNOL. METHODS IV, 1990, pages 121 - 152 |
SUTCLIFFE, J.G. ET AL., QUANT. BIOL., vol. 43, 1979, pages 77 - 90 |
YEE L ET AL: "DEFINTED MEDIA OPTIMIZATION FOR GROWTH OF RECOMBINANT ESCHERICIA COLI X90", BIOTECHNOLOGY AND BIOENGINEERING, WILEY & SONS, HOBOKEN, NJ, US, vol. 41, no. 2, 1 January 1993 (1993-01-01), pages 221 - 230, XP001064746, ISSN: 0006-3592, DOI: DOI:10.1002/BIT.260410208 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8791063B2 (en) | 2011-08-25 | 2014-07-29 | Hoffmann-La Roche, Inc. | Shortened tetranectin-apolipoprotein A-I fusion protein, a lipid particle containing it, and uses thereof |
US9139640B2 (en) | 2011-08-25 | 2015-09-22 | Hoffmann-La Roche Inc. | Shortened tetranectin-apolipoprotein A-1 fusion protein, a lipid particle containing it, and uses thereof |
US11332514B2 (en) | 2011-08-25 | 2022-05-17 | Hoffmann-La Roche Inc. | Cation and anion exchange chromatography method |
US20150011469A1 (en) * | 2012-01-19 | 2015-01-08 | University Of Cincinnati | Method of treating diabetes using non-glycosylated apolipoprotein a-iv |
US9951120B2 (en) * | 2012-01-19 | 2018-04-24 | University Of Cincinnati | Method of treating diabetes using non-glycosylated apolipoprotein A-IV |
WO2014128135A1 (en) | 2013-02-22 | 2014-08-28 | F. Hoffmann-La Roche Ag | Use of an amino acid auxotrophy cured prokaryotic strain for the recombinant production of a polypeptide |
EP3184547A1 (en) | 2015-10-29 | 2017-06-28 | F. Hoffmann-La Roche AG | Anti-tpbg antibodies and methods of use |
Also Published As
Publication number | Publication date |
---|---|
HK1181811A1 (en) | 2013-11-15 |
KR20130100301A (en) | 2013-09-10 |
ES2558751T3 (en) | 2016-02-08 |
US20150132802A1 (en) | 2015-05-14 |
CN103068967A (en) | 2013-04-24 |
RU2013112563A (en) | 2014-10-10 |
JP2016005461A (en) | 2016-01-14 |
EP2611900B1 (en) | 2015-11-25 |
KR101584414B1 (en) | 2016-01-13 |
RU2631001C2 (en) | 2017-09-15 |
EP2611900A1 (en) | 2013-07-10 |
BR112013004396A2 (en) | 2016-05-17 |
JP5798193B2 (en) | 2015-10-21 |
JP2013537432A (en) | 2013-10-03 |
MX2013002144A (en) | 2013-04-03 |
US20130323783A1 (en) | 2013-12-05 |
CN103068967B (en) | 2016-05-04 |
MX339227B (en) | 2016-05-17 |
CA2807428A1 (en) | 2012-03-08 |
US9845347B2 (en) | 2017-12-19 |
US8951756B2 (en) | 2015-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9845347B2 (en) | Alkaline feed | |
ES2401339T3 (en) | Materials and methods for efficient production of lactic acid | |
RU2600875C2 (en) | Microorganism able to produce l-amino acid and method for producing l-amino acid by using same | |
JP5978995B2 (en) | Process for producing chemicals by continuous fermentation | |
JP6649551B2 (en) | Method of producing succinic acid and other compounds using enhanced diffusion for sugar uptake | |
AU2608801A (en) | Increased lysine production by gene amplification | |
CN115109738B (en) | Recombinant escherichia coli for producing L-homoserine and application thereof | |
KR100464906B1 (en) | Process for preparing O-acetyl-L-serine by fermentation | |
CN111944857B (en) | Fermentation method for improving L-isoleucine yield | |
CN114717237B (en) | EP6 promoter and related biological material and application thereof | |
WO2016030373A1 (en) | Modified microorganism for improved production of fine chemicals on sucrose | |
US10155970B2 (en) | Use of an amino acid auxotrophy cured prokaryotic strain for the recombinant production of a polypeptide | |
CA2621280C (en) | Oxygen-regulated microorganisms | |
KR20220126610A (en) | Mutant of Corynebacterium glutamicum with enhanced L-lysine productivity and method for preparing L-lysine using the same | |
WO2015014829A1 (en) | Method for the recombinant production of a polypeptide in prokaryotic cells | |
KR20230053351A (en) | Mutant of Corynebacterium glutamicum with enhanced L-lysine productivity and method for preparing L-lysine using the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201180041407.3 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11748406 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011748406 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2807428 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2013/002144 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2013526412 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20137007871 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2013112563 Country of ref document: RU Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112013004396 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112013004396 Country of ref document: BR Kind code of ref document: A2 Effective date: 20130225 |